Bionor Pharma Nominates Celgene`s Jerome Zeldis, MD, PhD, to Board of Directors
Oslo 11.04.2012 - Bionor Pharma (OSE: BIONOR) today announced thatJerome ("Jerry") Zeldis, MD, PhD, has been nominated by the Company's ElectionCommittee to its Board of Directors.
Dr. Zeldis is an experienced leader with a
distinguished career at Celgene Corporation, one of the world's leading
biopharmaceutical companies with operations in more than 50 countries and
products sold in more than 70 markets in the Americas, EMEA, and APAC regions.
Dr. Zeldis is CEO of Celgene Global Health and Chief Medical Officer of Celgene
Corporation, based in Summit, New Jersey. The official election of the Board of
Directors will take place at Bionor's Annual General Meeting, 11 May.
"The technologies delivered by Bionor's researchers are unusually exciting,"
said Dr. Zeldis. "I believe in Bionor's platform and science as well as the
potential of these technologies to change the natural history of a variety of
challenging viral diseases."
Dr. Zeldis has also served as Celgene's Senior Vice President of Clinical
Research and Medical Affairs. He attended Brown University for an AB, MS,
followed by Yale University for an M Phil, MD, PhD in Molecular Biophysics and
Dr. Zeldis trained in Internal Medicine at the UCLA Center for the Health
Sciences and Gastroenterology at the Massachusetts General Hospital and Harvard
Medical School. He was Assistant Professor of Medicine at the Harvard Medical
School, Associate Professor of Medicine at University of California, Davis,
Clinical Associate Professor of Medicine at Cornell Medical School and Professor
of Clinical Medicine at the Robert Wood Johnson Medical School in New Brunswick,
He has published 112 peer reviewed articles and 24 reviews, book chapters, and
About Bionor Pharma ASA
Bionor Pharma is a biopharmaceutical, listed company based in Oslo, Norway (OSE:
BIONOR). The Company's investments in developing therapeutic vaccines are above
US$60 million. Bionor's vaccines are based on the proprietary technology
platform developed following more than two decades of research on peptides. The
vaccines are designed to safely activate each person's immune system to combat
The Company's lead investigational product, the HIV therapeutic vaccine Vacc-
4x, has completed a phase IIb multinational (USA, Germany, UK and Italy),
placebo controlled double-blind study, which found a statistically significant
reduction in viral load in treated subjects. The second HIV therapeutic
vaccine, Vacc-C5 is expected to be ready for first in man clinical trial
2Q 2012, and is developed to induce antibodies to HIV that can reduce immune
hyper activation associated with HIV infection. Subsequent to the Vacc-C5 phase
I/II trial, Bionor intends to combine Vacc-4x with Vacc-C5, a treatment that can
potentially revolutionize the management of HIV infections and could form the
basis for both a therapeutic and a preventative vaccine.
Bionor researchers will investigate three independent pathways to market for the
HIV vaccine candidates Vacc-4x and Vacc-C5, through further clinical studies
starting this year:
1. Vacc-4x revaccination in patients who participated in the phase IIb study,
which aims to further reduce the viral load set point, during periods where
patients are not on traditional medicine (antiretroviral therapy (ART)).
2. Vacc-4x combined with Revlimid® (lenalidomide), for patients with unmet
medical needs, no longer responding well to ART.
3. Vacc-C5 clinical trial phase I/II, subsequent Vacc-C5 in combination with
The Company's innovative technology platform is also well suited to the
development of vaccines for a wide range of other viral diseases, such as
Influenza, HCV (Hepatitis C), HPV (Human Papilloma Virus) and CMV
All preclinical studies with Vacc-Flu (Universal Influenza vaccine) and Vacc-HCV
(Hepatitis C vaccine), including toxicology are planned to be finalized in
second half 2012.
More information about Bionor Pharma, its research and products, is available
# # #
Bionor Pharma ASA, Oslo: +47 23 01 09 60/ Skien: +47 35 90 85 00
Lars H. Høie, Chairman